Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide in Renal Anemia: Switching to Pegmolesatide in Non-dialysis CKD Patients
NCT06946394Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peglmolesatide in anemia of chronic kidney disease (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Change in Hemoglobin Levels at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
peglmolesatide
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT06946394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946394.